Real-world Reductions in Migraine and Headache Days for Patients With Migraine Initiating Fremanezumab in Germany

被引：0

作者：

Heinze, A. ^{[1
]}

Totev, T. ^{[2
]}

Krasenbaum, L. ^{[3
]}

Terasawa, E. ^{[4
]}

Akcicek, H. ^{[5
]}

Hipp, J. ^{[5
]}

Sun, R. ^{[2
]}

Yim, E. ^{[2
]}

Driessen, M. ^{[5
]}

机构：

[1] Pain Clin Kiel, Migraine & Headache Ctr, Kiel, Germany

[2] Anal Grp Inc, Boston, MA USA

[3] Teva Branded Pharmaceut Prod R&D Inc, W Chester, PA USA

[4] Anal Grp Inc, New York, NY USA

[5] Teva Pharmaceut, Amsterdam, Netherlands

来源：

EUROPEAN JOURNAL OF NEUROLOGY | 2022年 / 29卷

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

EPO-075

引用

页码：419 / 419

页数：1

共 50 条

[1] Real-world Reductions in Migraine and Headache Days for Patients With Chronic and Episodic Migraine Initiating Fremanezumab in the US
Cohen, Joshua M.
Thompson, Stephen
Patterson-Lomba, Oscar
Driessen, Maurice
Seminerio, Michael
Carr, Karen
Mu, Fan
NEUROLOGY, 2021, 96 (15)
[2] REDUCTIONS IN MIGRAINE AND HEADACHE DAYS WITH QUARTERLY AND MONTHLY FREMANEZUMAB IN ADULT PATIENTS WITH MIGRAINE IN A US REAL-WORLD SETTING
Cohen, J.
Thompson, S.
Ayyagari, R.
Driessen, M.
Seminerio, M.
Carr, K.
Yim, E.
VALUE IN HEALTH, 2022, 25 (01) : S36 - S36
[3] Real-world reductions in migraine and headache days after initiating fremanezumab for US patients with migraine and prior use of another monoclonal antibody targeting the CGRP pathway
Driessen, M. T.
Patterson-Lomba, O.
Mu, F.
Thompson, S. F.
Seminerio, M. J.
Carr, K.
Sun, R.
Totev, T.
Yim, E.
Ayyagari, R.
Cohen, J. M.
HEADACHE, 2021, 61 : 141 - 141
[4] REDUCTIONS IN MIGRAINE AND HEADACHE DAYS AFTER INITIATING FREMANEZUMAB FOR PATIENTS WITH MIGRAINE AND PRIOR USE OF ANOTHER MONOCLONAL ANTIBODY TARGETING THE CGRP PATHWAY IN A US REAL-WORLD SETTING
Driessen, M.
Patterson-Lomba, O.
Mu, F.
Thompson, S.
Seminerio, M.
Carr, K.
Sun, R.
Totev, T.
Yim, E.
Ayyagari, R.
Cohen, J.
VALUE IN HEALTH, 2022, 25 (01) : S23 - S23
[5] US Real-world Effectiveness of Quarterly and Monthly Fremanezumab for Reducing Migraine Days and Headache Days in Adult Patients With Migraine
Cohen, Joshua M.
Thompson, Stephen
Ayyagari, Rajeev
Driessen, Maurice
Seminerio, Michael
Carr, Karen
Yim, Erica
NEUROLOGY, 2021, 96 (15)
[6] Real-world Reductions in Migraine-related Healthcare Resource Utilization for German Patients Initiating Fremanezumab
Heinze, A.
Totev, T.
Krasenbaum, L.
Terasawa, E.
Akcicek, H.
Hipp, J.
Sun, R.
Yilma, B.
Driessen, M.
EUROPEAN JOURNAL OF NEUROLOGY, 2022, 29 : 420 - 420
[7] Real-world Reductions in Monthly Migraine Days and Migraine-Related Healthcare Resource Utilization in UK Patients Using Fremanezumab
Afridi, S.
Totev, T.
Krasenbaum, L. J.
Terasawa, E.
Akcicek, H.
Dhiraj, D.
Sun, R.
Yilma, B.
Driessen, M. T.
JOURNAL OF HEADACHE AND PAIN, 2022, 23 (SUPPL 1):
[8] Real-world Reductions in Monthly Migraine Days and Migraine-Related Healthcare Resource Utilization in UK Patients Using Fremanezumab
Afridi, Shazia
Totev, Todor I.
Krasenbaum, Lynda J.
Terasawa, Emi
Akcicek, Hasan
Dhiraj, Dalbir
Sun, Rochelle
Yilma, Binyam
Driessen, Maurice T.
CEPHALALGIA, 2022, 42 (1_SUPPL) : 74 - 75
[9] Real-world data on reductions in migraine and headache days with fremanezumab treatment for US patients with chronic and episodic migraine: Results from a physician chart review study
Cohen, J. M.
Thompson, S. F.
Patterson-Lomba, O.
Driessen, M. T.
Seminerio, M. J.
Carr, K.
Mu, F.
HEADACHE, 2021, 61 : 70 - 71
[10] Real-world effectiveness after initiating fremanezumab treatment of 165 migraine patients in a regional headache center in Japan
Kikui, Shoji
Danno, Daisuke
Miyahara, Junichi
Sugyama, Hanako
Ota, Kuniko
Murakata, Kenji
Kashiwaya, Yoshihiro
Takeshima, Takao
CEPHALALGIA, 2023, 43 (1supp) : 236 - 236

← 1 2 3 4 5 →